| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8719536 | The Journal of Emergency Medicine | 2018 | 5 Pages |
Abstract
The clinical efficacy of activated prothrombin complex concentrates, idarucizumab, and recombinant factor VIIa remains unclear until further research is performed. Activated prothrombin complex concentrates, idarucizumab, and recombinant factor VIIa may be considered in patients with serious bleeding from dabigatran, after careful consideration of possible benefits and risks.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Emergency Medicine
Authors
Bryan D. PharmD, Michael E. MD, Steve B. MD, Mohannad F. MD, Gary M. MD,